首页 > 市场调查报告书 > 製药

药物开发临床实验临床开发

市场调查报告书

商品编码

1983179

週边神经病变治疗市场：依适应症、治疗方法、最终使用者和地区划分。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

出版日期: 2026年02月26日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计到 2026 年，週边神经病变治疗市场规模将达到 20.917 亿美元，到 2033 年将达到 27.159 亿美元。预计从 2026 年到 2033 年，该市场将以 3.8% 的复合年增长率成长。

分析范围		分析详情
基准年	2025	市场规模（2026 年）	2,091,700,000 美元
效能数据	2020-2024	预测期	2026-2033
预测期（2025-2032 年）复合年增长率	3.80%	预计金额（2033 年）	27.159亿美元

週边神经病变是周边神经的一种疾病。这些神经负责在中枢神经系统（大脑和脊髓）与身体其他部位之间传递讯息。週边神经病变可由创伤、感染疾病、代谢紊乱、遗传因素和接触毒素引起。其中最常见的原因之一是糖尿病。由第1型或第2型糖尿病引起的周边神经病变称为糖尿病性神经病变。週边神经病变患者通常将疼痛描述为刺痛、灼痛或麻刺感。在许多情况下，症状会改善，尤其是在病因是可治疗的疾病时。Lyrica）和度洛西汀（Cymbalta）等药物可以缓解週边神经病变的疼痛。

市场动态

全球週边神经神经病变治疗市场的主要企业正专注于市场渗透策略，例如产品上市和核准批准，预计这些策略将在预测期内推动市场成长。例如，2019年7月，印度製药公司Alembic Pharmaceuticals Limited宣布，其用于治疗週边神经病变疼痛的Pregabalin胶囊已获得美国食品药物管理局（FDA）的简化新药申请（ANDA）核准。此外，多个政府机构正致力于资助学术研究机构，以进行化疗引起的周边神经神经病变治疗的研究和开发，预计这也将在预测期内推动市场成长。例如，2018年11月，美国国家癌症研究所（NCI）向美国研究机构印第安纳大学医学院拨款230万美元。这项投资旨在加速一种名为APX3330的小分子标靶的研发，以预防或改善抗癌药物引起的化疗引起的周边神经病变（CIPN）。

本报告的主要特点

本报告对全球週边神经神经病变治疗市场进行了详细分析，包括预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
此外，它还确定了每个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本节根据以下参数介绍全球週边神经病变治疗市场主要企业的概况：公司概况、产品系列、主要亮点、财务绩效和策略。
本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
《全球週边神经病变治疗市场》报告面向该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过分析全球週边神经病变治疗市场中使用的各种策略矩阵来促进决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
欧洲
- 英国
- 德国
- 法国
- 义大利
- 西班牙
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 亚太其他地区
中东
- GCC
- 以色列
- 其他中东国家
非洲
- 北非
- 中非
- 南非

第八章竞争情势

热图分析
- Abbott Laboratories
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Johnson &Johnson
- Reddy's Laboratories Ltd
- Pfizer, Inc.
- Cipla Inc.
- Lupin Limited
- Averitas Pharma, Inc.
- NeuroBo Pharmaceuticals, Inc

第九章

分析方法
关于 Coherent Market Insights

简介目录

Product Code: CMI4363

Peripheral Neuropathy Treatment Market is estimated to be valued at USD 2,091.7 Mn in 2026 and is expected to reach USD 2,715.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2,091.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.80%	2033 Value Projection:	USD 2,715.9 Mn

Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes. Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy.

Market Dynamics

Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.

Key features of the study

This report provides an in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global peripheral neuropathy treatment market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Johnson & Johnson, Dr. Reddy's Laboratories Ltd, Pfizer, Inc., Cipla Inc., Lupin Limited, Averitas Pharma, Inc., and NeuroBo Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Market Segmentation

By Indication
- Diabetic Peripheral Neuropathy
- Chemotherapy-induced Peripheral Neuropathy
- Idiopathic Peripheral Neuropathy
- Others
By Treatment
- Pharmacological Therapies
- Pain Relievers
- Anti-seizure Medications
- Anti-depressants
- Non-pharmacological Therapies
- Transcutaneous Electrical Nerve Stimulation
- Plasma Exchange
- Others
By End User
- Hospital
- Ambulatory Centers
- Others
By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- Abbott Laboratories
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Johnson & Johnson
- Reddy's Laboratories Ltd
- Pfizer, Inc.
- Cipla Inc.
- Lupin Limited
- Averitas Pharma, Inc.
- NeuroBo Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By Treatment
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Pipeline Analysis
Reimbursement Scenario
Epidemiology
PEST Analysis
Regulatory Scenario
New Product Approvals/Launches
Acquisition and Collaboration
Market Trends

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Diabetic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)
Chemotherapy-induced Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)
Idiopathic Peripheral Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
  - Pain Relievers
  - Anti-seizure Medications
  - Anti-depressants
Non-pharmacological Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
  - Transcutaneous Electrical Nerve Stimulation
  - Plasma Exchange
  - Others

6. Global Peripheral Neuropathy Treatment Market, By End User, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2026-2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2028
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
- Abbott Laboratories
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Johnson & Johnson
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Reddy's Laboratories Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Pfizer, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Cipla Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Lupin Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Averitas Pharma, Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- NeuroBo Pharmaceuticals, Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views

9. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

週边神经病变治疗市场：依适应症、治疗方法、最终使用者和地区划分。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

市场动态

目录

第一章：分析目标与假设

第二章市场展望

第三章：市场动态、监管与趋势分析

第四章：全球週边神经神经病变治疗市场：依适应症划分（2026-2033 年）

第五章：全球週边神经病变治疗市场：依治疗方法划分（2026-2033 年）

第六章：全球週边神经病变治疗市场：依最终使用者划分（2026-2033 年）

第七章全球週边神经神经病变治疗市场：依地区划分（2026-2033 年）

第八章竞争情势

第九章

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2026-2033, (US$ Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2026-2033, (US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By End User, 2026-2033, (US$ Mn)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2026-2033, (US$ Mn)

8. Competitive Landscape

9. Section

週边神经病变治疗市场：依适应症、治疗方法、最终使用者和地区划分。

Peripheral Neuropathy Treatment Market, By Indication, By Treatment, By End User, By Geography

市场动态

目录

第一章：分析目标与假设

第二章 市场展望

第三章：市场动态、监管与趋势分析

第四章：全球週边神经神经病变治疗市场：依适应症划分（2026-2033 年）

第五章：全球週边神经病变治疗市场：依治疗方法划分（2026-2033 年）

第六章：全球週边神经病变治疗市场：依最终使用者划分（2026-2033 年）

第七章 全球週边神经神经病变治疗市场：依地区划分（2026-2033 年）

第八章 竞争情势

第九章

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Peripheral Neuropathy Treatment Market, By Indication, 2026-2033, (US$ Mn)

5. Global Peripheral Neuropathy Treatment Market, By Treatment, 2026-2033, (US$ Mn)

6. Global Peripheral Neuropathy Treatment Market, By End User, 2026-2033, (US$ Mn)

7. Global Peripheral Neuropathy Treatment Market, By Region, 2026-2033, (US$ Mn)

8. Competitive Landscape

9. Section

第二章市场展望

第七章全球週边神经神经病变治疗市场：依地区划分（2026-2033 年）

第八章竞争情势